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Available online 18 June 2019Background: Several publications have described differences in cross-sectional comparisons of gut microbiota
between patients with Parkinson's disease and control subjects, with considerable variability of the reported dif-
ferentially abundant taxa. The temporal stability of such microbiota alterations and their relationship to disease
progression have not been previously studied with a high-throughput sequencing based approach.
Methods:We collected clinical data and stool samples from 64 Parkinson's patients and 64 control subjects twice,
on average 2·25 years apart. Disease progression was evaluated based on changes in Uniﬁed Parkinson's Disease
Rating Scale and Levodopa Equivalent Dose, and microbiota were characterized with 16S rRNA gene amplicon
sequencing.
Findings:We compared patients to controls, and patients with stable disease to those with faster progression.
There were signiﬁcant differences between microbial communities of patients and controls when corrected for
confounders, but not between timepoints. Speciﬁc bacterial taxa that differed between patients and controls at
both timepoints included several previously reported ones, such as Roseburia, Prevotella and Biﬁdobacterium. In
progression comparisons, differentially abundant taxa were inconsistent across methods and timepoints, but
there was some support for a different distribution of enterotypes and a decreased abundance of Prevotella in
faster-progressing patients.
Interpretation: The previously detected gut microbiota differences between Parkinson's patients and controls
persisted after 2 years.Whilewe found some evidence for a connection betweenmicrobiota and disease progres-
sion, a longer follow-up period is required to conﬁrm these ﬁndings.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The early non-motor symptoms of Parkinson's disease (PD), such as
hyposmia and gastrointestinal (GI) disorders [1,2], have led to the hy-
pothesis that the disease could originate outside of the central nervous
system, for example in the olfactory bulb or the enteric nervous system
[3]. Research comparing nasal microbiota of PD patients and control
subjects has not revealed notable differences [4,5]. In contrast, several
studies have suggested that patients' gut microbiota differ from con-
trols' [5–16], although the differentially abundant taxa reported in
them vary considerably. This could be due to differences in subject
populations or methodology, such as PCR primers, sequencing
platforms, and statistical tools. Nevertheless, some microbialHelsinki University Hospital,
s).
. This is an open access article undercommunity alterations, including a decreased abundance of the family
Prevotellaceae, the genus Prevotella, and the species Prevotella copri
[6,9,12,13], and an increase in Akkermansia and Verrucomicrobiaceae
[5–7,9,11,12,15], Biﬁdobacterium and Biﬁdobacteriaceae [9,11,13], as
well as Lactobacillus and Lactobacillaceae [6,11,13], have been detected
multiple times.
Aside from a recent disease progression study using a qRT-PCR-
based assay [17], all PD gut microbiota publications have been case-
control studies with one timepoint. They have used varying approaches
to control for the effects of potential confounders, such as diet andmed-
ications. Diet inﬂuences the gut microbiome [18]. Since it has been hy-
pothesized to be an important determinant of the abundance of
Prevotellaceae [18], it could be associated to the decrease of that family
seen in PD [6,7]. Additionally, PD medications can affect gut microbiota
[6,11]. They are a particularly important confounderwhen studying dis-
ease progression, since progression is measured based on symptoms,
which respond to medications.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
The cause of idiopathic Parkinson's disease has been hypothe-
sized to involve an external agent, for example a pathogen, and
one potential route of entry for such an agent could be via the gas-
trointestinal system. The interactions of gutmicrobes and the cen-
tral nervous system, also knownas themicrobiota–gut–brain axis,
have recently become a topic of intense research. Within the past
5 years, a total of twelve studies from three continents have re-
ported differences in the composition of gutmicrobiota of patients
with Parkinson's disease when compared to non-parkinsonian
control subjects, showing promise for this novel field of research.
Added value of this study
Our study is the first to use a high-throughput sequencing based
approach to explore gut microbiota of Parkinson's patients at
two different timepoints. We show that the differences detected
at baseline can be replicated at a follow-up timepoint 2 years
later, and that there might be changes in gut microbiota composi-
tion in patients with faster disease progression.
Implications of all the available evidence
The consistent differences in gut microbiota between Parkinson's
patients and control subjects could lead to new diagnostic or ther-
apeutic modalities.
Table 1
Changes in subject inclusion/exclusion after pilot study.
n (recruited for pilot study) 152
Excluded from pilot study, not included in current study:
Excluded from pilot due to insufﬁcient read count, drop-out from follow-up 2
Excluded from pilot due to lack of matching subject 1
Excluded from pilot study, included in current study:
Not in pilot study due to insufﬁcient read count 2
Not in pilot study because sample received too late 2
Not in pilot study: nasal polyps; deemed eligible for follow-up study 1
n (pilot study) 144
Excluded after pilot study:
Exitus after pilot study 1
Drop-outs 11
Clinical exclusion: diagnosis changed to Lewy body dementia 1
Clinical exclusion: recent surgery 3
Technical exclusion: insufﬁcient reads from baseline sample 1
Technical exclusion: missing sample 1
Outlier exclusion: microbial community outlier 3
n (follow-up study) 128
Fig. 1. NMDS ordination of samples excluded as microbiome outliers.
692 V.T.E. Aho et al. / EBioMedicine 44 (2019) 691–707In the present study, we explore the gut microbiota of a previously
recruited group of PD patients and control subjects at baseline and
2 years later, while also considering their diet, medications, and other
clinical variables.
2. Materials and methods
2.1. Study subjects and clinical data
152 age and sex matched subjects (76 PD patients, 76 control sub-
jects) originally recruited for a pilot study in Parkinson's disease and
gut microbiota [6] were invited to a follow-up appointment on average
2·25 (SD:±0·20) years later. Out of the original subjectswho returned,
ninewere excluded,whileﬁve subjectswhose sampleswere not used in
the pilot study for various reasons were included at follow-up, bringing
the total number of subjects to 128 (64 PD patients, 64 control subjects;
Table 1, Fig. 1). The study was approved by the ethics committee of the
Hospital District of Helsinki andUusimaa. All participants gave informed
consent.
The subjects ﬁlled several questionnaires concerning non-motor
symptoms, including the Wexner constipation score [19], Rome III IBS
questionnaire [20], Non-Motor Symptoms Scale (NMSS) [21],
Swallowing Disturbance Questionnaire (SDQ) [22], Sialorrhea Clinical
Scale for PD (SCS-PD) [23], 15-item Geriatric Depression Scale (GDS-
15) [24], REM sleep behavior disorder screening questionnaire
(RBDSQ) [25] and Snifﬁn’ Sticks 16-item smell identiﬁcation score
[26]. The subjects' dietary habits were evaluated at follow-up with a
163 item Food Frequency Questionnaire (FFQ) with 9 frequency re-
sponse options (based on [27]). The severity of the patients' parkinso-
nian symptoms was assessed with the Uniﬁed Parkinson's Disease
Rating Scale (UPDRS) [28], and their total medication load was calcu-
lated using the Levodopa Equivalent Dose (LED) [29]. We also deter-
mined tremor and postural instability and gait difﬁculty (PIGD)symptom scores and derived motor phenotypes (postural instability
and gait difﬁculty (PIGD), tremor dominant (TD), or mixed (MX))
[30]. At follow-up, we also collected stool consistency information
using the Victoria Bowel Performance Scale (BPS) [31]; the patients
kept a diary of their scores for one week leading up to sampling, and
we used the weekly average stool consistency values for comparisons.
For comparisons ofmicrobiota and disease progression,we excluded
patients whowere on Deep Brain Stimulation at either timepoint, those
with missing UPDRS or LED values, and one patient whose LED score
had decreased considerably between the two timepoints due to adjust-
ment of overmedication symptoms. This left a subset of 56 PD patients
for progression analyses. To classify patients into stable or progressed,
we calculated changes in UPDRS I-III score (in the ON state) and LED be-
tweenbaseline and follow-up, divided each value by the number of days
between appointments, z-transformed these two variables, and added
them up. Based on the distribution of samples on this progression
scale, we chose the 3rd quartile as a cut-off, resulting in 41 stable and
15 progressed patients (Fig. 2). We also used this subset of patients
for additional analyses contrasting PD phenotypes, additionally exclud-
ing patients with a mixed (MX) phenotype, which resulted in a data set
with 21 TDpatients and 28 PIGD patients at baseline, and 20 TD patients
and 35 PIGD patients at follow-up.2.2. Sequencing and sequence analysis
Stool samples for both timepoints were collected at home by the
study subjects into collection tubes with pre-ﬁlled DNA stabilizer (PSP
Fig. 2. Histogram of the progression variable based on change in UPDRS I-III and LED. Legend: Solid vertical line represents the median, dashed vertical line represents the 3rd quartile,
which was used to categorize subjects into “stable” and “progressed”.
693V.T.E. Aho et al. / EBioMedicine 44 (2019) 691–707Spin Stool DNA Plus Kit, STRATECMolecular), and stored in the refriger-
ator until transport (for up to 3 days). Once received at the clinic, they
were transferred to−80 °C. Tominimize potential technical differences
between baseline and follow-up samples, we reanalysed the baseline
samples together with the follow-up samples, including new DNA ex-
tractions, PCR, and sequencing. Thus, the baseline samples, which had
been frozen after collection, then thawed for sequencing at the time of
the pilot study, re-frozen, and stored at−80 °C since, were thawed for
a second time for this follow-up study.Table 2
Correlations with PD status for potential microbiome confounders.
Variable Pearson correlation coefﬁcient with PD
Rome III 9–15 sum score 0.432
RLS 0.419
Wexner total 0.418
Rome III IBS criteria fulﬁlled 0.280
Medication anticholinergic 0.161
Diet PC1 0.145
BMI 0.094
Age at stool collection 0.061
Sex 0.016
MMSE total −0.159
Medication ACE-I/ARB −0.160
Medication Ca channel blockers −0.165
Medication warfarin −0.205
Medication statin −0.332
History TIA / ischemic stroke −0.364
Medication dopamine agonist 0.807
LED 0.753
Medication MAO inhibitor 0.736
NMSQuest total 0.714
Medication dopa 0.662
NMSS total 0.607
RBDSQ 0.580
SDQ total 0.529
SCS PD total 0.520
GDS 15 0.491
Medication COMT inhibitora 0.307
Snifﬁn’ Sticks −0.769
Table legend: RLS: Restless Legs Syndrome, IBS: Irritable Bowel Syndrome, PC: Principal Compo
sin-converting-enzyme inhibitor / angiotensin II receptor blocker, TIA: Transient Ischemic Att
Symptoms Questionnaire, NMSS: Non-Motor Symptoms Scale, RBDSQ: REM Sleep Behavior D
Sialorrhea Clinical Scale for PD, GDS 15: 15-item Geriatric Depression Scale, COMT: catechol-O
a COMT inhibitor variable used only for progression although |Pearson's r| b 0.5, since only PWe extracted bulk DNA from stool samples with the PSP Spin Stool
DNA Plus Kit (STRATEC Molecular). Each extraction batch included
one blank sample to assess potential contamination. The V3-V4 regions
of the 16S rRNA gene were ampliﬁed following a previously published
protocol [4], with the following changes: we used two technical repli-
cates (25 μL reactions) per patient sample, and a mixture of the univer-
sal bacterial primers 341F1–4 (5′ CCTACGGGNGGCWGCAG 3′) and
785R1–4 (5′ GACTACHVGGGTATCTAATCC 3′) [4] with partial Illumina
TruSeq adapter sequences added to the 5′ ends (F1; ATCTACACTCTTTCUse for PD status comparisons Use for progression comparisons
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
No Yes
No Yes
No Yes
No Yes
No Yes
No Yes
No Yes
No Yes
No Yes
No Yes
No Yes
No Yes
nent, BMI: BodyMass Index, MMSE:Mini-Mental State Examination, ACE-I/ARB: angioten-
ack, LED: Levodopa Equivalent Dose, MAO: Monoamine Oxidase, NMSQuest: Non-Motor
isorder Screening Questionnaire, SDQ: Swallowing Disturbance Questionnaire, SCS-PD:
-methyl transferase.
D patients take this medication.
Table 3
Clinical variables in Parkinson's patients and control subjects at each timepoint.
Variable Timepoint Control subjects (% (n) /
mean ± SD / median [IQR])
Parkinson's patients (% (n) /
mean ± SD / median [IQR])
p-value Test
n 64 64
Age (at ﬁrst stool collection) 64.45 ± 6.9 65.2 ± 5.52 0.499 t
Sex (% males) 50 (32) 51.56 (33) 1.000 Fisher
BMI Baseline 26.23 [24.1–28.05] 26.51 [24.25–29.36] 0.319 Wilcox
Follow-up 26.94 [24.32–28.64] 27.24 [23.95–30.08] 0.572 Wilcox
History of TIA or ischemic stroke Baseline 37.5 (24) 6.25 (4) b0.001 Fisher
Follow-up 37.5 (24) 7.81 (5) b0.001 Fisher
Medication: calcium channel blockers Baseline 15.62 (10) 7.81 (5) 0.271 Fisher
Follow-up 20.31 (13) 6.25 (4) 0.035 Fisher
Medication: statins Baseline 56.25 (36) 21.88 (14) b0.001 Fisher
Follow-up 50 (32) 20.31 (13) b0.001 Fisher
Medication: warfarin Baseline 14.06 (9) 1.56 (1) 0.017 Fisher
Follow-up 15.62 (10) 4.69 (3) 0.076 Fisher
NMSS total Baseline 8 [4–12] 40 [23.75–55] b0.001 Wilcox
Follow-up 6 [2–10.25] 40 [19.75–58.75] b0.001 Wilcox
Rome III constipation-defecation score (sum of items 9–15) Baseline 2 [1–4] 6 [2.75–11] b0.001 Wilcox
Follow-up 2 [0–3] 8 [2.75–11] b0.001 Wilcox
Rome III IBS criteria fulﬁlled Baseline 7.81 (5) 23.44 (15) 0.027 Fisher
Follow-up 7.81 (5) 35.94 (23) b0.001 Fisher
Table legend: Statistically signiﬁcant p-values aremarked in bold italic font. SD: StandardDeviation, IQR: Interquartile Range, BMI: BodyMass Index, TIA: Transient Ischemic Attack, NMSS:
Non-Motor Symptoms Scale, IBS: Irritable Bowel Syndrome.
Table 4
Clinical variables in stable and progressed Parkinson's patients at each timepoint.
Variable Timepoint Stable patients (n= 41) Progressed patients (n= 15)
% (n) / median [IQR] p-value
(baseline vs
follow-up)
% (n) / median [IQR] p-value
(baseline vs
follow-up)
p-value
(progressed
vs stable)
Test
Sex (% males) 53.66 (22) 46.67 (7) 0.765 Fisher
Age at stool collection 65 [61–69] 65 [62.5–66.5] 0.802 Wilcox
Age PD diagnosed 60 [58–64] 60 [57–65] 0.963 Wilcox
BMI Baseline 26.25 [24.15–29.8] 0.225 26.53 [25.28–28.24] 0.890 0.923 Wilcox
Follow-up 27.28 [24.27–30.21] 26.9 [23.89–29.89] 0.608
UPDRS I to III score
total
Baseline 45 [35–52] 0.004 36 [33–46.5] 0.004 0.201 Wilcox
Follow-up 38 [32–49] 48 [41–49] 0.020
UPDRS IV total Baseline 2 [0–3] 0.062 1 [0.5–2] 0.026 0.685 Wilcox
Follow-up 1 [0–5] 1 [1–6] 0.277
Hoehn & Yahr stage Baseline 2.5 [2–2.5] 0.735 2.5 [2–2.5] 0.021 0.453 Wilcox
Follow-up 2.5 [2–3] 2.5 [2.5–3] 0.038
Rome III IBS criteria
fulﬁlled
Baseline 24.39 (10) 0.467 6.67 (1) 0.330 0.255 Fisher
Follow-up 34.15 (14) 26.67 (4) 0.751
Jankovic subtypes
Baseline MX: 9.76 (4), PIGD: 53.66 (22), TD:
36.59 (15)
0.412 MX: 20.00 (3), PIGD: 40.00 (6), TD:
40.00 (6)
0.029 0.481 Fisher
Follow-up MX: 2.44 (1), PIGD: 53.66 (22), TD:
43.9 (18)
MX: 0 (0), PIGD: 86.67 (13), TD:
13.33 (2)
0.070
Medications
LED (mg) Baseline 420 [205–505] b0.001 340 [210–585] 0.001 0.774 Wilcox
Follow-up 505 [362–662] 604 [440–811.75] 0.177
Levodopa (%) Baseline 53.66 (22) 0.171 46.67 (7) 0.128 0.765 Fisher
Follow-up 70.73 (29) 80 (12) 0.735
Levodopa (mg) Baseline 100 [0–400] b0.001 0 [0−300] 0.034 0.715 Wilcox
Follow-up 300 [0–500] 350 [100–475] 0.708
COMT inhibitors (%) Baseline 12.2 (5) 1.000 6.67 (1) 0.080 1.000 Fisher
Follow-up 12.2 (5) 40 (6) 0.051
Entacapone (mg) Baseline 0 [0–0] 0.850 0 [0–0] 0.204 0.617 Wilcox
Follow-up 0 [0–0] 0 [0–750] 0.027
Acetylsalicylic acid
(%)
Baseline 17.07 (7) 1.000 46.67 (7) 0.450 0.037 Fisher
Follow-up 17.07 (7) 26.67 (4) 0.461
Statins (%) Baseline 12.2 (5) 1.000 46.67 (7) 0.710 0.010 Fisher
Follow-up 14.63 (6) 33.33 (5) 0.142
Pramipexole (mg) Baseline 0.26 [0–1.05] 0.169 0 [0–0.52] 0.098 0.160 Wilcox
Follow-up 0.26 [0–1.57] 0 [0–0] 0.001
Ropinirole (mg) Baseline 0 [0–0] 0.887 8 [0–8] 0.904 0.048 Wilcox
Follow-up 0 [0–0] 0 [0–8] 0.062
Table legend: Statistically signiﬁcant p-values aremarked in bold italic font. IQR: Interquartile Range, BMI: BodyMass Index, UPDRS: Uniﬁed Parkinson's Disease Rating Scale, IBS: Irritable
Bowel Syndrome, TD: tremordominant, PIGD: postural instability and gait difﬁculty,MX:mixeddisease phenotype, LED: LevodopaEquivalentDose, COMT: catechol-O-methyl transferase.
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Fig. 3.Biplot of principal component analysis of diet data, showing principal components 1
and 3. Legend: A. Component loadings; B. PD patients and controls, with 90% conﬁdence
ellipses.
695V.T.E. Aho et al. / EBioMedicine 44 (2019) 691–707CCTACACGACGCTCTTCCGATCT, F2; ATCTACACTCTTTCCCTACACGACGC
TCTTCCGATCTgt, F3; ATCTACACTCTTTCCCTACACGACGCTCTTCCGA
TCTagag, F4; ATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTtagtgt
and R1; GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT, R2; GTGACT
GGAGTTCAGACGTGTGCTCTTCCGATCTa, R3; GTGACTGGAGTTCAGACGT
GTGCTCTTCCGATCTtct, R4; GTGACTGGAGTTCAGACGTGTGCTCTTCCGA
TCTctgagtg). The additional nucleotides (small letters) are introduced
for mixing in sequencing. The two-step PCR and subsequent quantiﬁca-
tion, pooling, and puriﬁcation were done as described previously [4].
The obtained PCR amplicon pool was checked using Fragment Analyzer
(Advanced Analytical Technologies Inc., Ankeny, IA, USA). Every PCR
batch included a blank sample (no added DNA template) to assess po-
tential contamination. Finally, the PCR products were sequenced with
Illumina MiSeq (v3 600 cycle kit), with 325 bases for the forward and
285 bases for the reverse read.
The raw sequence data contained a total of 34 701 899 sequence
reads. These sequences are available at the EuropeanNucleotideArchive
with the accession number PRJEB27564. Primers were removed from
the reads using cutadapt (version 1.8.3) [32]. The reads were paired,
quality trimmed, taxonomically classiﬁed, and clustered into OTUs fol-
lowing mothur's Standard Operating Procedure (SOP) for MiSeq
(make.contigs: mothur 1.38.1, the rest of the workﬂow: mothur
1.39.5; SOP version last updated on 4 April 2018) [33,34]. The
following changes were made to the SOP parameters: insert = 40 and
deltaq = 10 in make.contigs; maxlength = 450 in the ﬁrst screen.seqs
step; start = 6428 and end = 23440 in the second screen.seqs step;
diffs=4 in pre.cluster. Additionally, singleton sequenceswere removed
with split.abunds (cutoff = 1) before running classify.seqs. The refer-
ences used were the full-length SILVA alignment release 128 for align.
seqs and the RDP 16S rRNA reference (PDS) version 16 for classify.
seqs.We inspected the extraction and PCR blank samples, which overall
had low amounts of sequence reads (Supplementary material: R Mark-
down), and since these did not suggest any overall problems with con-
tamination,we deleted these samples before downstream analyses. The
ﬁnal sequence data set (without the blanks) consisted of 18 867 278
good quality reads (median [IQR]: 73 078 [50 032–98 685]).
2.3. Statistics
All statistical comparisons and data visualization were performed
with R (v. 3.5.1) [35]. The full analysis workﬂow is available in the sup-
plementary materials (Supplementary material: R Markdown). In all
comparisons, p-values b0·05, or adjusted p-values b0·05 in the case of
multiple comparison corrected tests, were considered signiﬁcant. False
discovery rate [36] was used for multiple comparison correction. For
basic comparisons of potentially confounding clinical variables, we
used either Student's t-test, Wilcoxon signed rank test or Fisher's
exact test depending on the type and distribution of each variable, and
these comparisons were not corrected for multiple comparisons.
Figureswere plottedwith ggplot2 (v. 3.1.0), except for the diet principal
component analysis (PCA) biplot (which additionally utilized ggfortify
v. 0.4.5) and Euler plots (drawn with eulerr v. 5.0.0).
Food and nutrient variables from the FFQ were adjusted for energy
intake (divided by total energy intake in kilocalories and multiplied by
1000). For variable-speciﬁc comparisons, these continuous variables
were split into categories by quintiles. To look for dietary patterns, we
used PCA of a hand-picked set of 31 non-overlapping, continuous,
energy-adjusted and z-transformed food items.
The R-package phyloseq (v. 1.26.0) [37] was used for microbiota
data handling and calculating alpha diversity indices (observed rich-
ness, Shannon index and inverse Simpson index). Wilcoxon rank-sum
test and linear regressionwere used for statistical testing of alpha diver-
sity differences. Differences in Firmicutes/Bacteroidetes and Prevotella/
Bacteroides ratios were also compared with the Wilcoxon rank-sum
test. Enterotyping was run with the reference-based online tool [38],
and distributions of enterotypes were compared with the chi-squaretest, for which simulate.p.value = TRUE was used when comparing
PD patients subsetted according to progression, as the group sizes
were small.
Beta-diversity comparisons were done with vegan (v. 2.5–3) [39]
usingBray-Curtis dissimilarity of data subsampled to the lowest amount
of sequences in a sample (2201), on three different taxonomic levels
(OTU, genus and family). PERMANOVAwas runwith the command ado-
nis2,with theparameters by= “margins” and perm=9999 for all com-
parisons, except for the Timepoint + Parkinson+ single confounder as
well as the diet variable tests, which were run with 999 permutations.
To narrow down the lists of potential confounders for testing, we fo-
cused on those clinical variables that differed signiﬁcantly between
groups (PD/control or progressed/stable), and a few common con-
founders that did not (age, sex, body mass index). Variables that were
correlated with PD status (|Pearson's r| ≥ 0·5; Table 2) were only used
Fig. 4. 10 most common bacterial families at each timepoint. Legend: A. All study subjects by PD status; B. PD patients by progression status.
Fig. 5. Distributions of enterotypes in the subject groups. Legend: Showing control
subjects and PD patients classiﬁed by progression (excluding PD patients without a
progression classiﬁcation).
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r = 0·491, close to the cutoff and with high values mainly present in
PD patients at follow-up) and catechol-O-methyl transferase (COMT)
inhibitor use (Pearson's r = 0·307, but with no controls using themed-
ication)were also only used in thewithin PD group comparisons. To ex-
plore potential confounders for the PD/control comparisons, we ﬁrst
tested each variable for microbial community effects in a model that in-
cluded timepoint (baseline or follow-up), PD status, and the variable in
question. The variables that were signiﬁcant (adonis2 p b 0·05 on at
least one taxonomic level) in these single-confounder comparisons
were then tested together in a combined adonis2 model. As an alterna-
tive test, we used the envﬁt function (run with permutations = 9999),
ﬁtting variables that were signiﬁcant on at least one level with adonis2
onto a Nonmetric Multidimensional Scaling (NMDS) ordination
performed with the metaMDS function (run with try = 500). Beta-
diversity analysis for the progression comparisons was performed in a
similar manner, with the categorical disease progression variable
(progressed/stable) in place of the PD status variable.
For differential abundance comparisons, we used ANCOM (v. 2.0;
unpublished version shared online) [40,41], DESeq2 (v. 1.22.1) [42],
and random forests ([43], packages randomForest (v. 4.6–14) [44] for
the classiﬁcation, rfUtilities (v. 2.1–3) [45] for estimating the signiﬁ-
cance of the classiﬁcation, and rfPermute (v. 2.1.6) [46] for assessing
Table 5
Correlations for alpha diversity measures with variables of interest and confounders.
Observed richness Shannon Inverse Simpson
Pearson
correlation
p-value Adjusted
p-value
Pearson
correlation
p-value Adjusted
p-value
Pearson
correlation
p-value Adjusted
p-value
Timepoint 0.104 0.098 0.496 0.042 0.506 0.832 0.055 0.382 0.873
PD status 0.005 0.942 0.990 −0.023 0.718 0.908 −0.026 0.678 0.915
Meds CCB 0.136 0.030 0.266 0.216 0.001 0.042 0.217 b0.001 0.039
History ENT surgery 0.169 0.007 0.184 0.189 0.002 0.096 0.163 0.009 0.181
BMI −0.200 0.001 0.057 −0.159 0.012 0.190 −0.129 0.041 0.417
History CAD 0.105 0.096 0.496 0.168 0.007 0.153 0.169 0.007 0.181
Tobacco 100 in life 0.092 0.140 0.630 0.167 0.008 0.153 0.140 0.025 0.403
Selegeline mg −0.043 0.494 0.970 −0.124 0.048 0.487 −0.163 0.009 0.181
History IBS 0.149 0.017 0.232 0.116 0.064 0.517 0.131 0.036 0.417
History hyper-thyreosis −0.034 0.591 0.970 −0.143 0.022 0.299 −0.110 0.078 0.576
History appendectomy −0.054 0.392 0.970 −0.133 0.034 0.388 −0.110 0.078 0.576
History lactose intolerance 0.129 0.039 0.280 0.116 0.063 0.517 0.108 0.086 0.579
History hernia repair 0.013 0.835 0.990 0.101 0.108 0.729 0.135 0.031 0.417
History hypothyreosis 0.161 0.010 0.199 0.078 0.212 0.832 0.031 0.618 0.894
Wexner total 0.151 0.015 0.232 0.036 0.569 0.832 0.020 0.744 0.972
Rome III 9–15 sum score 0.212 0.001 0.052 0.031 0.616 0.832 0.010 0.872 0.985
Rome III IBS criteria
fulﬁlled
0.128 0.040 0.280 0.033 0.597 0.832 −0.007 0.913 0.985
Meds thyroxine 0.143 0.022 0.258 0.051 0.412 0.832 0.010 0.874 0.985
Food PC1 −0.127 0.042 0.280 −0.087 0.164 0.832 −0.055 0.379 0.873
Pramipexole mg −0.139 0.026 0.265 −0.028 0.657 0.845 −0.001 0.985 0.985
Table legend: Showing only variables with a signiﬁcant p-value in at least one comparison, and the PD status and Timepoint variables. Statistically signiﬁcant p-values are marked in bold
italic font. CCB: Calcium Channel Blockers, ENT: Ear, Nose and Throat, BMI: Body Mass Index, CAD: Coronary Artery Disease, IBS: Irritable Bowel Syndrome, PC: Principal Component.
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OTU, genus, and family levels, with data trimmed to include taxa that
had more than one read in at least 1/10 of samples (26 samples for PD
status comparisons, 11 for progression comparisons, and 10 for PD phe-
notype comparisons); additionally, OTUs were required to have at least
1000 sequence reads altogether. ANCOM and random forests were run
separately for baseline and follow-up, classifying data by PD status or
progression category. For ANCOM, we adjusted the PD/control compar-
isons for Rome III score and BMI, and the progression comparisons for
COMT inhibitor use, and chose the less stringent multiple comparison
correction option (multcorr = 2) and the 0.90 cutoff (prev.cut =
0.90) for proportion of zeroes. The results for the 0.6 detection level col-
umn were considered signiﬁcant. DESeq2 comparisons were corrected
for the same confounders and were run with the parameters ﬁtType
= “parametric” and sfType = “poscounts”. For the PD status compari-
sons, we used a model that was additionally corrected for subject
(model: Rome III score+ BMI+ PD : subject+ timepoint * PD) and ex-
tracted timepoint-speciﬁc contrasts from the results. Subjects that
lacked baseline BMI information (2 PD, 3 control) were excluded from
this analysis, which resulted in an unbalanced data set. Because of this
and to assess the robustness of the results, the PD status DESeq2 com-
parison was performed with a leave-one-out approach, excluding each
one of the 62 PD patients in turn, with the average FDR-adjusted p-
value of the 62 rounds as the ﬁnal result. DESeq2 comparisons for pro-
gression were run separately for each timepoint, correcting for COMT
inhibitor medication (model: COMT + Progression). PD phenotype
comparisons (TD vs PIGD, excluding patients with MX type) were run
with ANCOM and DESeq2, separately for each timepoint, and not
corrected for confounders due to the small number of subjects included
in this subgroup analysis.
3. Results
3.1. Clinical and diet data
Control subjects and PD patients were matched for age and sex in
the pilot study [6], and those who returned for the follow-up still had
similar distributions for these variables, as well as body mass index
(BMI) (Table 3). As expected, PD patients had higher scores on the
non-motor symptoms scale for Parkinson's disease (NMSS, p b0·001 at both timepoints), and the Rome III IBS questionnaire (p b
0·001 at both timepoints). Controls more commonly had a history of
transient ischemic attack (TIA) or ischemic stroke (p b 0·001 at both
timepoints) andwere on several medications more often than patients:
statins (p b 0·001 at both timepoints), warfarin at baseline (p (baseline)
= 0·017, p (follow-up) = 0·076), and calcium channel blockers (CCB)
at follow-up (p (baseline) = 0·271, p (follow-up) = 0·035) (Table 3).
Contrasting stable and progressed patients (Table 4), deﬁned based
on between-timepoint change in Uniﬁed Parkinson's Disease Rating
Scale (UPDRS) I-III sum and total medication load calculated using the
Levodopa Equivalent Dose (LED), there were no differences in basic de-
mographics. The UPDRS I-III sum was stable or even decreased slightly
between timepoints in stable patients (p = 0·004) and increased in
progressors (p=0·004).While therewas no statistically signiﬁcant dif-
ference in UPDRS I-III sum between groups at baseline (p = 0·201),
there was at follow-up (p = 0·020). LED was similar for both groups
at both timepoints and increased in both between timepoints (p (sta-
ble) b 0·001; p (progressors) = 0·001). Medications that differed be-
tween progression groups at baseline were acetylsalicylic acid (p =
0·037), statins (p = 0·010) and ropinirole (p (dose (mg)) = 0·048).
At follow-up, progressors used more COMT inhibitors (p (entacapone
(mg)) = 0·027; p (yes/no) = 0·051) and less pramipexole (p (dose
(mg)) = 0·001).
Regarding dietary data, there were no signiﬁcant differences in in-
takes of any dietary items between patients and controls, or stable and
progressed patients (Supplementary results). However, the ﬁrst princi-
pal component (PC1) of a Principal Component Analysis (PCA) seemed
to reﬂect diet healthiness (Table S1), with PD patientsmore often on the
unhealthy side (Fig. 3). We kept PC1 as a potential confounder to be
assessed in further analyses.3.2. Microbiota data
The 16S rRNA gene amplicon data contained 2836 OTUs, 198 genera
and 77 families. The most common taxa were similar for the PD and
control groups at both timepoints, with Ruminococcaceae and
Lachnospiraceae dominating both groups' microbiota (Fig. 4A).
Subsetting PD patients by progression status did not suggest major dif-
ferences in microbial communities between these groups (Fig. 4B).
Fig. 6. Interactions in linear regression of alpha diversity, PD status and confounders.
Legend: A. Shannon index and BMI; B. Inverse Simpson index and BMI, C. Observed
richness and Victoria Bowel Performance Scale.
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Firmicutes/Bacteroidetes ratio did not differ between patients and con-
trols, but Prevotella/Bacteroideswas higher in controls (p (baseline) =
0·052, p (follow-up) = 0·011). Comparing progressed and stable pa-
tients, Firmicutes/Bacteroidetes differed signiﬁcantly at baseline (p =
0·012) but not at follow-up, while Prevotella/Bacteroides did not differ
between groups.
Enterotype analysis suggested that PD patients in general, and
progressed patients in particular (Fig. 5), were overrepresented in the
Firmicutes-dominated enterotype. This difference was statistically sig-
niﬁcant at both timepoints when contrasting controls and all patients
(p (baseline) = 0·044; p (follow-up) = 0·025) or controls and
progressed patients (p (baseline) b 0·001; p (follow-up) = 0·043),
and at baseline when contrasting stable and progressed patients
(p (baseline)=0·016; p (follow-up)=0·291). Enterotype distribution
did not differ signiﬁcantly between stable patients and controls (p (both
timepoints) N 0·3).3.3. Alpha diversity
We explored alpha diversity (microbial community richness and
evenness) using three different indices (observed richness, Shannon, in-
verse Simpson). There was no difference between timepoints (p N 0·1,
all indices), controls and patients (p N 0·6, all indices, both timepoints),
stable and progressed patients (p N 0·2, all indices, both timepoints), or
PD phenotypes (postural instability and gait difﬁculty (PIGD) vs tremor
dominant (TD); p N 0·3, all indices, both timepoints). To look for effects
of potential confounders, we calculated their correlations with each
index (Table 5). The only variable with signiﬁcant adjusted p-values in
these comparisons was CCB use (adjusted p (Shannon) = 0·042; ad-
justed p (inverse Simpson) = 0·039). BMI and history of ear, nose
and throat (ENT) surgery had a signiﬁcant unadjusted p for all indices.
We also found interactions between PD status and BMI in linear regres-
sion for the Shannon and inverse Simpson indices, and between PD sta-
tus and average Victoria Bowel Performance Scale (BPS) score (follow-
up only) when modelling observed richness (Fig. 6, Supplementary re-
sults, Table S2). Dietary variables were not associated with differences
in alpha diversity (Supplementary results).
3.4. Beta diversity
Regarding beta diversity (between-sample community dissimilar-
ity), subjects' microbial communities did not differ between timepoints
in any comparison, but they did between patients and controls (p (PD
status) b 0·017, all comparisons; Table 6A–C, Fig. 7). The confounding
variables with the most consistent effects were constipation scores
(Rome III: p ≤ 0·001, all comparisons; Wexner: p ≤ 0·004 in all single-
confounder comparisons, dropped from further comparisons due to col-
linearity) and BMI (p b 0·025 in all comparisons except envﬁt test at
genus and family level); two medication variables, CCB and ACE-I/ARB
(angiotensin-converting-enzyme inhibitor / angiotensin II receptor
blocker), and PC1 from the diet analysis were also signiﬁcant in more
than one comparison (Table 6B-C, Fig. 8). Separate beta diversity com-
parisons for dietary variables revealed no strong dietary confounders
(Table S3, Supplementary results).
Comparing progressed and stable patients, therewere no beta diver-
sity differences between timepoints nor for progression (Table 7A–C),
while COMT inhibitor use had a very signiﬁcant community effect (p ≤
0·001, all comparisons except the envﬁt test on genus and family levels;
Table 7B–C). Other confounders which were signiﬁcant in more than
one comparison were statins, SCS-PD total, and NMSQuest. There were
no differences for beta diversity between PD phenotypes (Supplemen-
tary results).
3.5. Differential abundance of microbial taxa
We used three differential abundance comparison methods, all of
which suggested several taxa as differing signiﬁcantly between PD pa-
tients and controls (ANCOM: 2 families, 1 genus and 6 OTUs for baseline
and 3 families, 3 genera and 8 OTU for follow-up; random forests: 4
families, 5 genera and 33 OTUs for baseline, 3 families, 9 genera and
29 OTUs for follow-up; DESeq2: 3 families, 5 genera and 2 OTUs at base-
line, 3 families and 5 genera at follow-up; Fig. 9, Supplementary mate-
rial: Table S4). All random forest classiﬁers were signiﬁcantly better
than chance (p ≤ 0·046 for all comparisons; Table S5). Combining the
results of the three methods, a handful of taxa overlapped at one or
both timepoints, mainly the families Biﬁdobacteriaceae, Prevotellaceae,
and Puniceicoccaceae, and the genera Biﬁdobacterium, Roseburia,
Prevotella, and Clostridium XIVa (Table 8, Fig. 9, Fig. 10). A few other
taxa reported as differentially abundant in previous studies were signif-
icant only according to random forests: the family Lachnospiraceae and
the genus Blautia at baseline, and Lactobacillaceae and Lactobacillus at
follow-up. Considering the confounders included in DESeq2, 2 OTUs,
the genera Clostridium and Coprococcus, and the family Clostridiaceae 1
Table 6
Beta diversity comparisons of PD patients, control subjects and confounding variables.
A. Adonis: Timepoint + PD status (no confounders)
Level p-value (Timepoint) p-value (PD status)
OTU 0.898 b0.001
Genus 0.544 b0.001
Family 0.647 b0.001
B. Adonis: Timepoint + PD + single confounder
Variable p-value (OTUs) p-value (genera) p-value (families)
BMI 0.001 0.002 0.003
ACEI / ARB 0.032 0.046 0.018
Rome III 9–15 sum score 0.001 0.001 0.001
Wexner total 0.001 0.002 0.004
Diet PC1 0.003 0.009 0.064
CCB 0.017 0.031 0.183
RLS 0.034 0.085 0.043
TIA / ischemic stroke 0.007 0.103 0.186
Age at stool collection 0.153 0.170 0.266
Sex 0.053 0.106 0.065
Anticholinergics 0.287 0.828 0.882
Statins 0.068 0.370 0.453
Warfarin 0.564 0.610 0.339
MMSE total 0.730 0.561 0.310
Rome III IBS criteria fulﬁlled 0.229 0.191 0.276
C. Timepoint + PD status + multiple confounders
p-value
Test Level Timepoint Parkinson BMI TIA / ischemic stroke ACEI / ARB CCB Rome III 9–15 sum score Diet PC1 RLS
Adonis2 OTU 0.888 0.006 0.002 0.009 0.020 0.003 b0.001 0.013 0.086
Genus 0.510 0.016 0.002 0.085 0.168 0.007 0.001 0.096 0.110
Family 0.625 0.017 0.025 0.349 0.044 0.121 0.001 0.227 0.133
Envﬁt OTU 0.995 0.001 0.010 0.948 0.188 0.073 b0.001 0.063 NA
Genus 0.083 0.001 0.372 0.660 0.097 0.162 b0.001 0.560 NA
Family 0.129 0.001 0.607 0.981 0.953 0.044 b0.001 0.303 NA
Table legend: Statistically signiﬁcant p-values are marked in bold italic font. OTU: Operational Taxonomic Unit, BMI: BodyMass Index, ACE-I/ARB: angiotensin-converting-enzyme inhib-
itor / angiotensin II receptor blocker, PC: Principal Component, CCB: Calcium Channel Blocker, RLS: Restless Legs Syndrome, TIA: Transient Ischemic Attack, MMSE: Mini-Mental State
Examination, IBS: Irritable Bowel Syndrome.
Fig. 7. NMDS ordination illustrating microbial community differences between PD patients and control subjects. Legend: Also showing centroid locations for microbial genera reported as
differentially abundant between the two groups in previous studies.
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Fig. 8. Genus-level NMDS ordination plots of the main confounding variables. Legend: A.
BMI, diet and Rome III score; B. Calcium channel blockers (CCB) medication; C. ACE-I/
ARB medication.
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with the Rome III score (Supplementary material: Table S4C).
Biﬁdobacteriaceae were not associated with PD status according to
DESeq2 at either timepoint (Table 8). Finally, theDESeq2model enabled
the detection of microbes with a difference in between-timepoint
trends when comparing controls and PD patients, but we found no
such taxa.
Analyses contrasting progressed patients to stable ones also resulted
in lists of several differentially abundant taxa (Supplementarymaterial:
Table S6A\\C). However, random forest models failed to differentiate
progressors and stable patients better than chance; the only comparison
with a signiﬁcant p-value was OTU level at follow-up (p= 0·044), and
even there, the difference between actual and randomly permuted error
values was small (Table S7). The differential abundance results of the
three methods did not overlap substantially. One low-abundance,Table 7
Beta diversity comparisons of stable and progressed PD patients and confounding
variables.
A. Adonis: Timepoint + progression category (no confounders)
Level p-value (Timepoint) p-value (progression)
OTU 1.000 0.245
Genus 0.945 0.344
Family 0.850 0.142
B. Adonis: Timepoint + progression category single confounder
Variable p-value
(OTUs)
p-value
(genera)
p-value
(families)
SDQ 0.012 0.007 0.010
COMT inhibitors 0.001 0.001 0.001
Levodopa entacapone
(mg)
0.001 0.001 0.001
Entacapone (mg) 0.001 0.001 0.001
NMSQuest 0.003 0.018 0.137
SCS-PD 0.001 0.005 0.166
Statins 0.010 0.038 0.065
GDS 15 0.016 0.395 0.308
L-dopa 0.025 0.061 0.088
NMSS 0.018 0.070 0.306
RBDSQ 0.007 0.131 0.079
Ropinirole (mg) 0.365 0.045 0.223
Dopamine agonists 0.050 0.365 0.074
MAO inhibitors 0.545 0.826 0.442
Snifﬁn’ Sticks 0.422 0.342 0.093
Acetylsalicylic acid 0.430 0.824 0.943
PIGD score Jankovic 0.057 0.176 0.484
Pramipexole (mg) 0.075 0.060 0.059
C. Timepoint + progression category + multiple confounders
adonis2 envﬁt
Variable p-value
(OTUs)
p-value
(genera)
p-value
(families)
p-value
(OTUs)
p-value
(genera)
p-value
(families)
Timepoint 0.865 0.515 0.582 0.797 0.372 0.074
Progression 0.396 0.334 0.204 0.330 0.592 0.889
COMT
inhibitors
0.001 0.001 0.001 b0.001 0.295 0.888
NMSQuest 0.036 0.027 0.321 0.227 0.024 0.102
SCS-PD 0.002 0.035 0.271 0.031 0.427 0.479
Statins 0.042 0.214 0.442 0.475 b0.001 0.005
SDQ 0.114 0.116 0.067 NA NA NA
GDS 15 0.127 0.804 0.660 NA NA NA
L-dopa 0.421 0.344 0.208 NA NA NA
NMSS 0.447 0.216 0.498 NA NA NA
RBDSQ 0.062 0.513 0.312 NA NA NA
Ropinirole
(mg)
0.411 0.098 0.440 NA NA NA
Table legend: Statistically signiﬁcant p-values are marked in bold italic font. OTU: Opera-
tional Taxonomic Unit, SDQ: Swallowing Disturbance Questionnaire, COMT: catechol-O-
methyl transferase, NMSQuest: Non-Motor Symptoms Questionnaire, SCS-PD: Sialorrhea
Clinical Scale for PD,GDS 15: 15-itemGeriatric Depression Scale, NMSS:Non-Motor Symp-
toms Scale, RBDSQ: REM Sleep Behavior Disorder Screening Questionnaire, MAO: Mono-
amine Oxidase, PIGD: postural instability and gait difﬁculty.
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Fig. 9. Differentially abundant taxa between control subjects and PD patients according to three different tools. Legend: A. Baseline; B. Follow-up.
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702 V.T.E. Aho et al. / EBioMedicine 44 (2019) 691–707unclassiﬁed Lachnospiraceae OTU was signiﬁcant according to all
methods at follow-up; DESeq2 and random forests agreed on one Strep-
tococcus OTU and the family Streptococcaceae at baseline, and three
OTUs, the genus Asteroleplasma, and the family Anaeroplasmataceae at
follow-up; and a single Biﬁdobacterium OTU, which was more common
in progressors at follow-up, was supported by both ANCOM and ran-
dom forests (Table 9). The genus Prevotellawasmore abundant in stableTable 8
Summary of differential abundance results contrasting PD patients and control subjects.
Baseline
Level Previously
published
Relative abundance
(%, mean ± SD)
p-value
Control PD ANCOM
Biﬁdobacteriaceae Family Yes 2.629 ± 2.719 6.528 ±
8.573
s.s.
Prevotellaceae Family Yes 4.345 ± 9.22 0.725 ± 2.12 s.s.
Rikenellaceae Family Yes 2.201 ± 2.035 3.494 ±
2.899
n.s.
Lachnospiraceae Family Yes 22.478 ±
10.241
16.48 ±
9.121
n.s.
Pasteurellaceae Family Yes 0.036 ± 0.097 0.009 ±
0.027
n.s.
Lactobacillaceae Family Yes 0.032 ± 0.124 0.28 ± 1.199 n.s.
Puniceicoccaceae Family No 0.045 ± 0.103 0.01 ± 0.029 n.s.
Biﬁdobacterium Genus Yes 2.628 ± 2.717 6.524 ± 8.57 s.s.
Roseburia Genus Yes 7.014 ± 6.944 3.588 ±
4.096
n.s.
Prevotella Genus Yes 4.187 ± 9.003 0.659 ±
2.102
n.s.
Anaerotruncus Genus Yes 0.056 ± 0.079 0.071 ±
0.084
n.s.
Blautia Genus Yes 2.419 ± 1.516 1.829 ±
1.598
n.s.
Lactobacillus Genus Yes 0.031 ± 0.125 0.278 ±
1.197
n.s.
Clostridium XlVa Genus No 1.971 ± 2.631 1.83 ± 3.265 n.s.
Otu0003 Roseburia OTU Yes 6.506 ± 6.71 3.115 ±
3.742
n.s.
Otu0007
Biﬁdobacterium
OTU Yes 1.563 ± 1.808 4.579 ±
6.456
s.s.
Otu0024 Blautia OTU Yes 0.904 ± 0.875 0.649 ±
0.903
n.s.
Otu0027 Ruminococcus OTU Yes 0.679 ± 0.959 0.437 ±
0.895
n.s.
Otu0030 Alistipes OTU Yes 0.404 ± 0.861 0.955 ±
1.392
s.s.
Otu0036 Roseburia OTU Yes 0.483 ± 0.757 0.468 ±
1.279
n.s.
Otu0041 Alistipes OTU Yes 0.278 ± 0.247 0.448 ±
0.499
n.s.
Otu0055 Prevotella OTU Yes 0.344 ± 1.243 0.197 ±
1.048
n.s.
Otu0062 Blautia OTU Yes 0.446 ± 0.576 0.266 ±
0.358
n.s.
Otu0098 Bacteroides OTU Yes 0.105 ± 0.239 0.29 ± 0.599 n.s.
Otu0109 Ruminococcus OTU Yes 0.343 ± 1.142 0.122 ±
0.844
n.s.
Otu0110 Ruminococcus OTU Yes 0.189 ± 0.332 0.136 ±
0.279
n.s.
Otu0131 Bacteroides OTU Yes 0.183 ± 0.654 0.079 ±
0.256
n.s.
Otu0363 Lactobacillus OTU Yes 0.019 ± 0.107 0.056 ±
0.225
n.s.
Otu0379 Alistipes OTU Yes 0.001 ± 0.003 0.041 ± 0.2 n.s.
Otu0464 Lactobacillus OTU Yes 0.002 ± 0.009 0.004 ±
0.016
n.s.
Otu0468
Faecalibacterium
OTU Yes 0.016 ± 0.026 0.009 ±
0.019
n.s.
Otu0513 Anaerotruncus OTU Yes 0.006 ± 0.006 0.011 ±
0.011
n.s.
Table legend: This table includes (1) taxa that are differentially abundant according to more th
abundant in previous studies and have p b 0.1 with at least one method at either timepoint in t
Taxonomic Unit, SD: Standard Deviation, s.s.: statistically signiﬁcant, n.s.: not signiﬁcant.patients at both timepoints according to DESeq2, while the family
Prevotellaceae only differed at follow-up (Fig. 11; Table 9; Supplemen-
tary results: Table S6C). There were as many or more taxa associated
with COMT inhibitors in the DESeq2 results as there werewith progres-
sion, although these were also inconsistent across timepoints (Supple-
mentary results: Table S6C). Among them, Biﬁdobacterium was more
common in COMT users than non-users at follow-up.Follow-up
Relative abundance
(%, mean ± SD)
p-value
Random
Forests
DESeq2 Control PD AN-COM Random
Forests
DESeq2
0.129 0.151 2.189 ± 3.531 5.919 ± 8.256 s.s. 0.040 0.150
0.010 0.002 2.972 ± 4.882 1.395 ± 3.474 s.s. 0.079 0.002
0.030 0.075 2.479 ± 2.559 2.836 ± 2.131 n.s. 0.386 0.172
0.020 0.990 21.787 ±
8.964
17.753 ±
8.198
n.s. 0.416 0.995
0.089 0.625 0.059 ± 0.28 0.014 ± 0.052 n.s. 0.158 0.585
0.129 0.993 0.04 ± 0.159 0.226 ± 0.867 n.s. 0.040 0.995
0.010 0.993 0.032 ± 0.061 0.01 ± 0.03 s.s. 0.010 0.995
0.089 0.244 2.188 ± 3.53 5.917 ± 8.256 s.s. 0.040 0.410
0.020 0.147 6.683 ± 6.162 4.395 ± 5.298 s.s. 0.010 0.121
0.050 0.042 2.85 ± 4.854 1.306 ± 3.355 s.s. 0.030 0.043
0.079 0.986 0.119 ± 0.501 0.098 ± 0.163 n.s. 0.693 0.990
0.040 0.742 2.63 ± 1.847 2.429 ± 2.334 n.s. 0.644 0.927
0.356 0.989 0.04 ± 0.159 0.221 ± 0.862 n.s. 0.030 0.996
0.168 b0.001 2.136 ± 2.589 1.501 ± 2.076 n.s. 0.020 b0.001
0.020 0.342 6.144 ± 5.933 4.109 ± 5.027 n.s. 0.020 0.275
0.079 0.613 1.518 ± 3.155 4.029 ± 6.243 s.s. 0.089 0.692
0.020 1.000 1.057 ± 1.14 0.712 ± 0.884 n.s. 0.020 1.000
0.089 1.000 0.832 ± 1.515 0.604 ± 1.23 n.s. 0.960 1.000
0.010 1.000 0.711 ± 1.627 0.623 ± 1.134 n.s. 0.535 1.000
0.089 1.000 0.534 ± 0.771 0.282 ± 0.689 n.s. 0.030 1.000
0.099 1.000 0.33 ± 0.342 0.412 ± 0.37 n.s. 0.713 1.000
0.129 1.000 0.493 ± 1.758 0.342 ± 1.413 n.s. 0.079 1.000
0.030 0.049 0.328 ± 0.46 0.217 ± 0.299 n.s. 0.198 0.111
0.030 0.499 0.111 ± 0.22 0.231 ± 0.407 n.s. 0.079 0.371
0.465 1.000 0.369 ± 1.175 0.001 ± 0.002 s.s. 0.010 1.000
0.020 1.000 0.205 ± 0.519 0.14 ± 0.322 n.s. 0.139 1.000
0.406 0.998 0.209 ± 0.613 0.049 ± 0.205 s.s. 0.020 0.995
0.792 1.000 0.016 ± 0.122 0.006 ± 0.035 n.s. 0.050 1.000
0.317 1.000 0.004 ± 0.033 0.047 ± 0.236 n.s. 0.020 1.000
0.446 1.000 0.001 ± 0.006 0.044 ± 0.236 n.s. 0.010 1.000
0.723 1.000 0.021 ± 0.033 0.007 ± 0.016 n.s. 0.050 1.000
0.030 0.998 0.006 ± 0.005 0.012 ± 0.019 n.s. 0.208 0.995
an one method at either timepoint, and (2) taxa that have been reported as differentially
his study. Statistically signiﬁcant p-values are marked in bold italic font. OTU: Operational
703V.T.E. Aho et al. / EBioMedicine 44 (2019) 691–707When contrasting PD phenotypes (TD and PIGD), ANCOM detected
no differentially abundant families or genera, and only 2 OTUs at base-
line, while DESeq2 detected longer lists of taxa (Supplementary results;
Table S8).4. Discussion
Several studies have demonstrated that in healthy subjects,
intersubject variability is greater than temporal variability in individuals
[47,48]. Based on our results, this seems to also hold true for PD patients.
In contrast to the lack of differences between timepoints, the microbial
communities clearly differed between PD patients and controls, which
is in line with previous studies of PD and gut microbiota: they haveFig. 10. Genera and families that differ signiﬁcantly between control subjects and PD patients. L
have been reported as differing in a previous publication and have p b 0.1 at one timepoint accconsistently reported differences in beta diversity between PD patients
and controls [ 5–7,10–16].
The results of differential abundance comparison methods based on
different statistical approaches can vary widely [49], offering one expla-
nation for the varying results of the speciﬁc taxa reported in previous
publications on PD and gut microbiota [5–16]. Other potential sources
of variation include differences in the subjects' demographics and clini-
cal details, technical differences in the sampling, storage and sequencing
protocols, and different sample sizes. Our study ranks among the larger
publications when it comes to the number of subjects, but it is still pos-
sible that we havemissed some subtle effects due to not having enough
samples.
In the present study, we used three different tools to look for taxa
that differ between PD patients and controls, and our results underlinedegend: Showing taxa that differ at either timepoint according tomore than onemethod, or
ording to at least one method.
Table 9
Summary of differential abundance results contrasting progressed and stable PD patients.
Baseline Follow-up
Relative abundance (%,
mean ± SD)
p-value Relative abundance (%,
mean ± SD)
p-value
Level Stable Progressed AN-COM Random
Forests
DESeq2 Stable Progressed AN-COM Random
Forests
DESeq2
Streptococcaceae Family 0.207 ±
0.584
0.614 ±
1.316
n.s. 0.010 0.001 0.299 ±
0.904
0.398 ± 0.74 n.s. 0.663 0.176
Anaeroplasmataceae Family 0.426 ±
1.792
0.371 ±
1.125
n.s. 0.198 0.966 0.133 ±
0.596
0.311 ± 1.05 n.s. 0.010 b0.001
Prevotella Genus 0.964 ±
2.571
0.147 ±
0.493
n.s. 0.554 b0.001 1.966 ± 4.04 0.187 ±
0.678
n.s. 0.386 b0.001
Asteroleplasma Genus 0.191 ±
1.022
0.302 ±
1.113
n.s. 0.455 0.767 0.133 ±
0.596
0.31 ± 1.051 n.s. 0.050 b0.001
Otu0148 Biﬁdobacterium OTU 0.06 ± 0.252 0.143 ±
0.498
n.s. 0.465 0.862 0.051 ±
0.125
0.744 ±
1.324
s.s. 0.010 0.330
Otu0327 Lachnospiraceae
unclassiﬁed
OTU 0.013 ±
0.032
0.104 ±
0.282
n.s. 0.050 0.965 0.021 ±
0.091
0.178 ±
0.357
s.s. 0.010 0.016
Otu0118 Ruminococcaceae
unclassiﬁed
OTU 0.084 ±
0.102
0.246 ±
0.221
n.s. 0.010 0.094 0.135 ±
0.261
0.165 ± 0.14 n.s. 0.040 0.838
Otu0166 Ruminococcaceae
unclassiﬁed
OTU 0.069 ±
0.102
0.166 ±
0.203
n.s. 0.020 0.531 0.082 ±
0.097
0.194 ±
0.227
n.s. 0.040 0.603
Otu0222 Phascolarctobacterium OTU 0.091 ±
0.281
0 ± 0 n.s. 0.436 0.002 0.043 ±
0.137
0 ± 0 n.s. 0.911 0.000
Otu0111 Streptococcus OTU 0.127 ±
0.369
0.46 ± 1.187 n.s. 0.050 0.007 0.217 ±
0.643
0.254 ±
0.501
n.s. 0.743 0.438
Otu0042 Coprococcus OTU 0.344 ± 1.26 0.002 ±
0.002
n.s. 0.733 b0.001 0.511 ± 1.44 0.004 ±
0.011
n.s. 0.525 0.000
Otu0268 Desulfovibrio OTU 0.059 ±
0.168
0.034 ±
0.131
n.s. 0.475 b0.001 0.042 ±
0.102
0.001 ±
0.002
n.s. 0.792 0.009
Otu0115 Lachnospiraceae
unclassiﬁed
OTU 0.167 ±
0.404
0.607 ±
2.296
n.s. 0.921 0.018 0.04 ± 0.086 0.776 ±
2.121
n.s. 0.010 0.014
Otu0049 Ruminococcaceae
unclassiﬁed
OTU 0.26 ± 0.707 0.595 ±
0.919
n.s. 0.040 0.864 0.286 ±
0.663
0.56 ± 0.896 n.s. 0.030 0.297
Otu0241 Clostridiales unclassiﬁed OTU 0.029 ±
0.054
0.044 ±
0.064
n.s. 0.446 0.698 0.015 ±
0.022
0.084 ±
0.159
n.s. 0.040 0.020
Otu0084 Clostridium IV OTU 0.313 ±
0.978
0.335 ±
0.726
n.s. 0.485 0.864 0.071 ±
0.091
0.275 ±
0.345
n.s. 0.010 0.001
Table legend: This table includes (1) bacterial taxa that are differentially abundant at one timepoint according tomore than onemethod, or (2) at both timepoints according to onemethod.
Statistically signiﬁcant p-values are marked in bold italic font. OTU: Operational Taxonomic Unit, SD: Standard Deviation, s.s.: statistically signiﬁcant, n.s.: not signiﬁcant.
704 V.T.E. Aho et al. / EBioMedicine 44 (2019) 691–707the variation between methods: the lists of detected taxa overlapping
between methods were short. The only taxa signiﬁcant at both
timepoints according to multiple methods were Prevotella and
Prevotellaceae [6,9,12,13]. Some taxa reported to differ between PD pa-
tients and control subjects by earlier studies, such as Akkermansia
[5,7,11,12] and Verrucomicrobiaceae [5–7,11,13,15], did not differ
signiﬁcantly in our comparisons, while many others, including
Biﬁdobacterium and Biﬁdobacteriaceae [9,11,13], Lactobacillus and
Lactobacillaceae [6,11,13], Lachnospiraceae [7,11,15] and Roseburia
[7,11], were inconsistent across tools and timepoints. An additional,
new taxon that was detected as signiﬁcant at both timepoints in our
study was Puniceicoccaeae, but as this family mainly contains environ-
mental species [50] and was present at a very low abundance (mean
± SD (%): 0·025 ± 0·065), it seems unlikely to be of interest.
The baseline samples compared in this analysis were a subset of our
earlier study [6], but the new results differed from our previous ones.
For example, the new analyses did not support a difference in
Lactobacillaceae at baseline. As the earlier study used different PCR
primers, sequencing platform, and statistical tools, it is not unexpected
that the results also differ. Additionally, the baseline stool samples
were stored longer and thawed twice, compared to the follow-up sam-
ples which were stored for a briefer period and only thawed once. Al-
though we could detect no overall differences between timepoints in
alpha or beta diversity comparisons, some of the variation in lists of dif-
ferentially abundant taxa could relate to this.
Regarding disease progression, the differentially abundant taxa sup-
ported by more than one method did not overlap between timepoints
aside from two unclassiﬁed Lachnospiraceae OTUs. According to
DESeq2, Prevotella was more abundant in stable subjects at bothtimepoints, and Prevotellaceae at follow-up.We also contrasted patients
with different disease phenotypes (TD and PIGD). Although the differ-
ence in Enterobacteriaceae between phenotypes detected in our pilot
studywith themetastats method [6] was signiﬁcant in the resequenced
baseline data when tested with DESeq2, there was no signiﬁcant differ-
ence for this family at follow-up. The family Anaeroplasmataceae and the
genus Asteroleplasma were signiﬁcant in both progression and PD phe-
notype comparisons, but both taxa had values close to zero in nearly
all samples, so these are likely to be false positives caused by the outlier
subjects.
One previous publication on gutmicrobiota and PD progression, also
with a 2-year follow-up period, found that stable and deteriorated pa-
tients had similar microbiota at each timepoint, although
Biﬁdobacterium was less abundant in deteriorated patients at baseline
[17]. Several taxa, including Prevotella, decreased between timepoints,
and the abundances of Biﬁdobacterium and B. fragilis were negatively
correlated to UPDRS I [17]. In our study, we saw no overall decreasing
trend for Prevotella, although the genus was more abundant in stable
subjects. Biﬁdobacterium was more abundant in COMT inhibitor users
at follow-up. The previous study assessed only selected microbial taxa
and did not consider the changes in medication over time in their pro-
gression classiﬁcation [17]. To get a more universal measure of PD
symptom severity than puremotor function, and to reduce dependency
on the rater, we chose to use the sumof UPDRS I-III as a symptom sever-
ity measure for progression calculations [51]. For practical reasons,
UPDRS-III assessments in medication OFF-state were only available for
the follow-up timepoint of our cohort. Therefore, we chose to use
UPDRS-III in medication ON-state for our calculations [51]. Thus,
UPDRS scores are to some degree inﬂuenced by PD medication load. A
Fig. 11.Genera and families that differ signiﬁcantly between stable and progressed PDpatients. Legend: Showing taxa that differ at one timepoint according tomore than onemethod, or at
both timepoints according to a single method.
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this score, could falsely classify patients with progressed disease as sta-
ble e.g. if they had been undertreated at baseline, and this was compen-
sated during the follow-up interval by overproportional medication
increase. Thismay have inﬂuenced the results of the previous longitudi-
nal study on microbiota in PD [17]. If disease severity is assessed in ON-
state, theprogression classiﬁermust at the same timeaccount for the PD
medication load that may make motor symptom severity appear less
than it actually is. The severity measure that we used to classify our pa-
tients by progression is driven by symptom severity and medication
load and thus increase in either onewill increase the probability of a pa-
tient being classiﬁed as a progressor. Even though not commonly used
previously, our measure is based on a widely used indicator of disease
severity (UPDRS I-III in ON-state) and is adjusted for medication load,
which we deem essential in this context.
Bearing in mind the methodological differences, the discordant re-
sults of the two follow-up studies are unsurprising. Taken together,
they seem to imply that there is no strong microbial signal associated
with PD progression. However, measuring progression is challenging.
A 2-year follow-up period is short, and the number of patients classiﬁed
as progressed in our comparisons was low (15 patients). A longer
follow-up period and a larger patient cohort might be required to ob-
serve progression-related changes in microbiota.
The lowered abundance of the family Prevotellaceae in PD was a key
ﬁnding of our pilot study [6]. Considering the results of our follow-up
analysis, it remains a taxon of interest. Based on our FFQ comparisons,
the abundance of this taxon was not strongly affected by dietary factors.The difference in Prevotella abundance also remained signiﬁcant when
correcting for Rome III constipation score, although this does not entirely
exclude the possibility that the results are confounded by the constipa-
tion commonly seen in PD [52]. Prevotella is a common colonizer of the
human gut, and the dominant taxon in one of the three suggested
enterotypes [38]. It has been linked to numerous medical conditions,
its role varying from beneﬁcial to detrimental, possibly depending on
the species or strain [53]. Two PD studies have reported a lowered abun-
dance particularly for the species P. copri [10,12]. Additionally, one study
found the genus less abundant in PD patients with IBS-like symptoms
[1]. We have no strain level information in the present study, as 16S
rRNA gene amplicon sequencing lacks the resolution for reliably deﬁning
species or strains. Hopefully, future research into the features of different
Prevotella taxa will shed more light on their potential relationship to PD.
Numerous factors, such as BMI, sex, diet, and medications, can inﬂu-
ence gut microbiota [11,18,54]. Our subjects represent a small and fairly
uniform population, and patients and controls werematched for age and
sex, but somedifferences between groups are inevitable: for example, PD
patients have more GI symptoms than the general population [1,2,52],
and take PD-speciﬁc medications. Additionally, stroke or TIA were
more common among our controls, who also used CCBs, statins andwar-
farin more often than patients. Diversity comparisons suggested that
CCBs might inﬂuence gut microbiota diversity, but with so few subjects
using them (baseline: 15, follow-up: 17), evaluating the signiﬁcance of
this effect is difﬁcult. The same was true for COMT inhibitors: they
were associated with differences in beta diversity and many differen-
tially abundant taxa but were only used by a small subset of patients
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linked to microbiota changes [6,11], future studies of PD andmicrobiota
should consider COMT inhibitors as an important confounder.
Sincediet couldunderlie somemicrobiotadifferences detected in earlier
studies, we also collected FFQ data. PC1 from a dietary PCA implied a less
healthy diet for patients and was associated with beta diversity differences
in single-confounder comparisons, but in multiple-confounder models it
was only signiﬁcant on OTU level with one test, while other variables (PD
status, Rome III score, BMI) remained signiﬁcant on multiple taxonomic
levels with two different tests. Overall, diet did not appear to be a major
confounder. Dietary ﬁbre, which is thought to inﬂuence gut microbiota
(and speciﬁcally the abundance of Prevotella), was included in all diet com-
parisons, with separate variables for total ﬁbre, insoluble ﬁbre, and soluble
ﬁbre. There were no differences in ﬁbre consumption between PD patients
and controls, and ﬁbre was not associated with signiﬁcant differences in
alpha or beta diversity. Another potentially important confounder, the use
of probiotics,was equally insigniﬁcant in all comparisons. This is likely to re-
ﬂect the fact that our data set is small, particularly considering the semi-
quantitative nature of FFQs, and may not have enough statistical power to
catch the microbial inﬂuences of these diet variables.
Intriguing incidental ﬁndings were the interactions between PD and
BMI in relation to alpha diversity indices that include richness and even-
ness, and PD and stool consistency for observed richness. An inverse
correlation between BMI and alpha diversity has been reported in sev-
eral previous publications [55–57]; in our analyses, this effect was no-
ticeably weaker in PD patients. Additionally, the inverse correlation
between the BPS stool consistency scale and richness, analogous to a
previously reported inverse correlation between richness and the Bris-
tol Stool Scale [58], was also stronger in control subjects than PD pa-
tients. These results offer support for PD patients having abnormal gut
microbial communities that do not follow trends seen in analyses with
healthy subjects. Statistical modelling that goes beyond linear regres-
sion between alpha diversity and a few key confounders could offer fur-
ther information regarding the complex relationships between PD and
the other variables associated with changes in alpha diversity.
5. Conclusions
In this study, we have shown that the differences in gut microbiota
of PD patients and controls persist at follow-up sampling 2 years later.
As all previous studies have only included data from a single timepoint,
this is an important ﬁrst conﬁrmation of replicability of such ﬁndings.
Our lists of differentially abundant taxa between patients and controls
included many previously reported bacteria (such as Biﬁdobacterium,
Prevotella, Lactobacillus, and Roseburia), although the results varied con-
siderably between statistical tools. Progressed PD patients had a
Firmicutes-dominated enterotype more often than stable patients or
control subjects. Additionally, Prevotella, a genus already shown to be
less abundant in PD patients compared to controls, also appears less
abundant in patients with faster disease progression. This further un-
derlines the potential importance of this genus in PD. A longer follow-
up period might be warranted for capturing the trends in microbial
community changes during disease progression.
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